Zymeworks has announced the results of its Phase 1 clinical trial for a new drug targeting ovarian cancer. The trial aimed to evaluate the safety, tolerability, and preliminary efficacy of the drug in patients diagnosed with the disease. The findings indicate that the drug was well-tolerated among participants, with some patients showing positive responses to the treatment. Further studies are anticipated to confirm these results and assess the drug's potential in larger patient populations.
Related Articles
Don't miss out on breaking stories and in-depth articles.